Publication Name	World Journal of Clinical Oncology
Manuscript ID	31780
Country	Spain

Received	2016-12-07 10:46
Peer-Review Started	2016-12-07 13:56
To Make the First Decision	2017-02-15 12:12
Return for Revision	2017-02-20 12:11
Revised	2017-02-26 03:33
Second Decision	2017-02-27 14:48
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2017-03-13 12:15
Articles in Press	2017-03-13 12:15
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2017-03-30 14:44
Publish the Manuscript Online	2017-04-07 08:24

ISSN	2218-4333 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Editorial
Article Title	Translating new data to the daily practice in second line treatment of renal cell carcinoma: The role of tumor growth rate
Manuscript Source	Invited Manuscript
All Author List	Enrique Grande, Olga Martínez-Sáez, Pablo Gajate Borau and Teresa Alonso-Gordoa
Funding Agency and Grant Number
Corresponding Author	Enrique Grande, MD, PhD, Medical Oncology Department, Ramón y Cajal University Hospital, Ctra. Colmenar Viejo km 9100, 28034 Madrid, Spain. egrande@oncologiahrc.com
Key Words	Axitinib; Everolimus; Cabozantinib; Kidney cancer; Nivolumab; Renal cell; Sequence; Second line; Sorafenib; Tumor-growth rate
Core Tip	The landscape of renal cell carcinoma has dramatically changed in the last decade. Today, at least 6 agents are approved after failure with cytokines, sunitinib or pazopanib in first line treatment. Lack of reliable biomarkers to select the best treatment in daily practice is somewhat frustrating. Therefore, our decisions in real practice are based on safety profiles, patient’ co-morbidities and physician experience or preference. Here we debate the pros and cons of the tumor-growth rate as a tool to select second line systemic treatment after failure to a prior tyrosine kinase-inhibitor in patients with advanced renal cell carcinoma.
Publish Date	2017-04-07 08:24
Citation	Grande E, Martínez-Sáez O, Gajate-Borau P, Alonso-Gordoa T. Translating new data to the daily practice in second line treatment of renal cell carcinoma: The role of tumor growth rate. World J Clin Oncol 2017; 8(2): 100-105
URL	http://www.wjgnet.com/2218-4333/full/v8/i2/100.htm
DOI	http://dx.doi.org/10.5306/wjco.v8.i2.100

Full Article (PDF)	WJCO-8-100.pdf
Full Article (Word)	WJCO-8-100.doc
Manuscript File	31780-Review.docx
Answering Reviewers	31780-Answering reviewers.pdf
Audio Core Tip	31780-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	31780-Conflict-of-interest statement.pdf
Copyright License Agreement	31780-Copyright assignment.pdf
Supplementary Material	Supplementary_Material_20161206193901.pptx
Peer-review Report	31780-Peer-review(s).pdf
Scientific Misconduct Check	31780-Scientific misconduct check.pdf
Scientific Editor Work List	31780-Scientific editor work list.pdf